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Abstract 35 
Despite the availability of treatment guidelines and inhaled medications for asthma and chronic 36 
obstructive pulmonary disease (COPD), much remains to be done to lessen the burden of these 37 
respiratory diseases for patients. The challenge of selecting effective and efficacious drugs for 38 
patients is a key focus area for healthcare professionals. Here we discuss the concept of “drivers of 39 
effectiveness”— features of a medicine which may increase or decrease its effectiveness in the 40 
presence of real-world factors — and highlight the importance of considering these drivers in the 41 
early stages of drug development, and exploring their impact in carefully designed pragmatic trials. 42 
Using the Salford Lung studies (SLS) in asthma and COPD as an illustrative example, we discuss 43 
various features of the inhaled corticosteroid/long-acting 2-agonist combination, fluticasone 44 
furoate/vilanterol (FF/VI), as potential drivers of effectiveness that may have contributed to the 45 
improved patient outcomes observed with initiation of FF/VI versus continuation of usual care in the 46 
UK primary care setting. 47 
 48 
 49 
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Background 53 
The worldwide burden of asthma and chronic obstructive pulmonary disease (COPD) remains high. 54 
The global state of progress in improving health outcomes for patients with asthma has largely 55 
plateaued and there has been little advancement towards helping a large proportion of patients 56 
whose asthma remains uncontrolled [1,2]. Similarly, COPD continues to be associated with high 57 
morbidity [3,4] and according to 2016 World Health Organization estimates, COPD was the third 58 
leading cause of mortality worldwide [5]. Guidelines for the management of asthma and COPD have 59 
existed for, and evolved over, many decades. Likewise, effective medicines for asthma and COPD 60 
have been available for many years. Highly controlled efficacy studies, for example the Gaining 61 
Optimal Asthma ControL (GOAL) study [6], have demonstrated that good asthma control is possible 62 
in the majority of patients. Despite these evidence-based guidelines and medicines with proven 63 
efficacy in highly controlled clinical trials, we appear to be failing to make the headway we might 64 
expect in lessening the burden of respiratory diseases for patients. 65 
The reasons for poor asthma control and lack of progress in asthma care have been widely 66 
described [1,2,7–10]. Haughney et al [10] have defined some of the obstacles to achieving good 67 
asthma control (Box 1). Similar barriers have been described for COPD [3,11]. 68 
 69 
Box 1. Obstacles to achieving good asthma control 
 Wrong diagnosis 
 Incorrect choice of inhaler or poor technique 
 Lifestyle choices (e.g. smoking) 
 Co-morbidities (e.g. rhinitis, obesity) 
 Individual variation in response to treatment 
 Patient beliefs and adherence 
 70 
While there is a strong evidence base supporting the efficacy of currently available 71 
medicines for asthma and COPD, their prescription by clinicians and use by patients is suboptimal 72 
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and leaves many patients at risk due to poor disease control. Incorrectly prescribed and poorly 73 
utilized treatments are also costly and lead to inefficiency in healthcare systems. The challenge of 74 
selecting effective and efficacious drugs for patients is a key focus area for healthcare professionals. 75 
A medicine’s efficacy is usually demonstrated under near-ideal conditions in double-blind 76 
randomized controlled trials [DBRCTs]) [12]; such trials typically recruit highly selected patient 77 
populations and operate under experimental, highly monitored and controlled conditions, which 78 
may limit the generalizability of their findings to the broader disease population. Effectiveness can 79 
be thought of as the interaction of a medicine’s proven efficacy with factors related to patients, 80 
actual medication use, and healthcare systems, which results in the effects observed in patients in 81 
the everyday clinical setting (Figure 1). Abenhaim [13] has described the concept of “drivers of 82 
effectiveness” — features of a medicine that may increase or decrease the effectiveness of that 83 
medicine in the presence of real-world factors. These drivers of effectiveness encompass a range of 84 
factors relating to the patient, the medicine, and the environment, including: (i) patient 85 
acceptability, including perceived or real side effects and tolerability; (ii) the medicine’s efficacy; (iii) 86 
persistence of correct use of the medicine; (iv) adherence; and (v) affordability, cost-effectiveness 87 
and economic factors, e.g. the price the patient may pay for medication and the patient’s age. Other 88 
patient-related factors and factors relating to the healthcare system and medical practice, such as 89 
such as vaccination programs, self-management plans in asthma or outreach teams in COPD, may 90 
also impact a medicine’s effectiveness and will clearly vary in different healthcare settings. 91 
Abenhaim’s team and the Innovative Medicines Initiative GetReal project have suggested 92 
that drivers of effectiveness should be considered early in the drug development cycle [14,15] and 93 
that their impact be explored in appropriately designed studies alongside traditional DBRCTs. As 94 
DBRCTs are deliberately designed to remove potential confounders, they are unlikely to allow 95 
modifiers of effectiveness to be expressed. It is therefore important, as part of clinical development, 96 
that drugs are tested in their intended real-world setting, with minimal intervention (i.e. mimicking 97 
everyday clinical practice and preserving the usual behaviors of patients and healthcare 98 
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professionals and closely as possible) in order to evaluate the medicine’s true effectiveness. The 99 
inhaled corticosteroid (ICS)/long-acting 2-agonist (LABA) combination, fluticasone furoate/vilanterol 100 
(FF/VI [Relvar]; GlaxoSmithKline plc.) was tested in a real-world effectiveness study program. The 101 
Salford Lung Studies (SLS) in asthma and COPD evaluated the effectiveness and safety of initiating 102 
once-daily inhaled FF/VI versus continuing usual maintenance inhaler therapy (usual care [UC]) in 103 
the UK primary care setting. UC comprised a wide variety of inhaled and oral medicines as 104 
prescribed by each individual general practitioner (GP) taking part in the study and was not 105 
determined by protocol — a major difference compared with typical DBRCTs. The SLS designs and 106 
results have been published previously [16–20]. These open-label, pragmatic, randomized, 107 
controlled effectiveness trials demonstrated the benefits of initiating FF/VI versus continuing UC in 108 
terms of their respective primary endpoints of improvements in asthma control and reduction in 109 
COPD exacerbations [19,20]. The studies were designed to enable GPs to function as study 110 
investigators, with changes in treatment during the study permitted based on their clinical opinions.  111 
The results of the SLS raise the questions of what features were driving the improved 112 
effectiveness observed for FF/VI versus UC, and how could those drivers of effectiveness help to 113 
address some of the obstacles for improving care for patients with asthma and COPD? 114 
 115 
Potential drivers of effectiveness in asthma and COPD  116 
FF/VI delivered via the ELLIPTA dry powder inhaler was designed as an improvement over 117 
fluticasone propionate/salmeterol delivered via the Diskus inhaler. An overview of factors thought 118 
to be important in driving clinical effectiveness is presented in Figure 2. Various features of FF/VI 119 
could potentially have improved effectiveness and patient outcomes with initiation of FF/VI versus 120 
continuation of UC in the SLS, as discussed below. 121 
 122 
Once-daily dosing 123 
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Patient adherence with inhaled medications for the treatment of asthma and COPD is low [21,22] for 124 
reasons including patient beliefs, side effects, dosing frequency, and poor inhaler technique [21–23]. 125 
In studies of adherence in the real-world setting, adherence rates have been reported to be as low 126 
as 10% and typically between 20–40% [24–28]. 127 
Once-daily treatment administration has the potential to encourage/increase adherence 128 
compared with twice-daily administration, as evidenced in medications for asthma and other 129 
indications [29–31]. FF/VI was the first once-daily inhaled ICS/LABA combination to be broadly 130 
available worldwide. In the SLS, adherence was assessed using the Medication Adherence Report 131 
Scale for Asthma (MARS-A) questionnaire and patients’ prescription records were accessed through 132 
their electronic case report forms. The MARS-A was used to gather patients’ patterns of medication 133 
use (e.g. “I only take it when I need it”), and the number of prescriptions issued was used to 134 
estimate the proportion of days covered (PDC) by study medication as a surrogate for treatment 135 
adherence. Both methods have their limitations: the MARS-A is a validated questionnaire to assess 136 
self-reported adherence, but self-reported behavior does not always reflect actual behavior, such as 137 
unintentional non-adherence. Furthermore, the measure captures patients’ general tendencies of 138 
how they take their medication, not actual adherence per se. The use of prescribing data has 139 
considerable limitations in assessing adherence, as it only records the number of prescriptions 140 
issued, and not the number dispensed to, or actually used by, patients. Nevertheless, in SLS asthma, 141 
the reported mean PDC was 82.3% for FF/VI and 78.2% for UC and in SLS COPD was 85.0% for FF/VI 142 
and 82.4% for UC [32,33]. As planned, no statistical testing has been conducted on these data. 143 
Further assessment of adherence to FF/VI through electronic monitoring devices will aid better 144 
understanding of this driver of effectiveness [34–37]. 145 
 146 
Rapid onset and long duration of action of the active molecules 147 
The rapid onset of action of a medication may result in a perceived benefit to the patient that may 148 
encourage treatment adherence [38]. A longer duration of action beyond the licensed dosing 149 
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interval may mean that the medicine is more “forgiving” of the non-adherence commonly 150 
encountered in everyday practice (including irregular dosing and use) [39,40]. The onset and 151 
duration of action of FF/VI has been assessed in asthma. Studies evaluating the bronchodilator 152 
effects of FF/VI using serial lung function measures in asthmatic patients have demonstrated an 153 
onset of action as early as 15 minutes [41] and a 72-hour duration of bronchodilation after a single 154 
dose [42]; slower in onset than formoterol (within minutes [43,44]) and longer in duration of action 155 
than formoterol or salmeterol (at least 12 hours) [43–45]. Bardsley et al examined the duration of 156 
airway anti-inflammatory action of FF/VI by serially measuring fractional exhaled nitric oxide (FeNO) 157 
over a 14-day treatment period with FF/VI and over 21 days following cessation of therapy. Full 158 
suppression of FeNO in asthma was estimated to last for up to 3 days, with effective suppression 159 
continuing for up to 18 days, and improvements in forced expiratory volume in 1 second and peak 160 
expiratory flow lasting for 3–4 days after cessation of treatment [46]. While there are limited 161 
comparative data on the duration of anti-inflammatory action for ICS, separate studies in patients 162 
treated with budesonide have reported FeNO return to baseline values within 7 days of cessation of 163 
treatment [47]. 164 
 165 
Device features and design 166 
Effective drug delivery systems enable the controlled introduction of a medicine into the body, while 167 
also improving drug efficacy and safety [48]. The dosage form and device can directly impact on 168 
treatment success and patient adherence [48]. Critical errors — those that can be defined as errors 169 
resulting in limited or no medication being delivered to the lung — have been associated with major 170 
impacts on respiratory symptoms and healthcare consumption [49,50]. The ELLIPTA inhaler has been 171 
shown to be superior to other commonly used inhalers for the administration of ICS/LABA 172 
medicines, in terms of patient preference for its design features of dose counter, ease of use, and 173 
dosing regimen [51]. Furthermore, it has been shown that fewer patients make critical errors with 174 
the ELLIPTA inhaler compared with a range of other ICS/LABA inhalers, and that the ELLIPTA inhaler 175 
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requires less teaching time than other inhalers [52]. In studies evaluating the dose delivery achieved 176 
through ELLIPTA, patients received a dose close to the label claim with inspiratory flow rates of 30 177 
L/min and above 30 L/min peak inspiratory flow rate. Furthermore, studies have shown that asthma 178 
and COPD patients across a range of disease severities achieved a flow of 43 L/min or above [53]. In 179 
everyday practice, a simple inhaler that requires less time to teach the correct technique, is easy to 180 
use, has a low potential for patients to make critical errors, delivers adequate dose across a broad 181 
range of inspiratory flow rates, and is preferred by patients, will be a positive driver of effectiveness 182 
since there will be greater confidence that the medication has been optimally delivered. 183 
 184 
Tolerability 185 
A theoretical consequence of some drivers of effectiveness is that, while the likelihood of correct 186 
and adequate dosing increases, the benefits in terms of positive outcomes might be outweighed by 187 
an increased risk of side effects. Tolerability and adverse events reported in phase lll clinical studies 188 
of FF/VI in patients with asthma and COPD were similar to those seen with the fluticasone 189 
propionate/salmeterol combination [54–56]. In the SLS, serious adverse event rates were very 190 
similar for FF/VI and UC [19,20]. Modeling studies have suggested that FF may have a better 191 
therapeutic index than other inhaled steroids [57]. 192 
 193 
Discussion 194 
Asthma and COPD guidelines and regulatory and payer frameworks have long favoured DBRCTs as 195 
constituting the highest level of evidence [3,58]. Although Cochrane highlighted the importance of 196 
understanding the effectiveness of medicines back in 1972 [12], his enthusiasm has not been 197 
broadly shared. Pragmatic real-world study designs have not been universally adopted and drug 198 
development has instead continued to focus on evaluating efficacy within highly controlled trials in 199 
highly selected patient populations. As a result, we are left struggling to assess the external validity 200 
of the results of such studies and medicine development programs. As well designed effectiveness 201 
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studies are undervalued due to their pragmatic design features, the overriding focus on efficacy 202 
evaluation is likely to have hampered the implementation of drivers of effectiveness early in drug 203 
development processes.  204 
The SLS were world-first, pragmatic, randomized, controlled trials conducted in the routine 205 
UK clinical practice setting to evaluate a pre-licensed inhaled medicine [16]. The trials were open-206 
label to maintain their pragmatic design; however, this meant open-label for patients, GPs, 207 
pharmacists, other healthcare providers, and most of the study team. This could have introduced 208 
bias, particularly as FF/VI would have been either unlicensed or newly licensed while the studies 209 
were ongoing. In an attempt to minimise this bias, sponsor study team members who were involved 210 
in the development of the analysis plan and the actual data analyses were blinded to patients’ 211 
individual therapies up until the formal unblinding of the studies, which occurred after the databases 212 
had been finalized. The SLS exemplify that by designing drivers of effectiveness into a medicine, the 213 
medicine alone can improve patient outcomes compared to other medications in the same drug 214 
class. 215 
It is difficult to assess which components of the composite drivers of effectiveness play the 216 
biggest part in improving patient outcomes. Moreover, these drivers are likely to reinforce one 217 
another, whereby the physical features of the medicine are improving outcomes and, thus, patient-218 
perceived benefits, which in turn may enhance the belief that the medicine is making a difference. 219 
For example, a longer duration of action of a medicine is likely to mitigate any sub-optimal 220 
adherence, thus altering the impact of the latter on actual and perceived symptom control. Likewise, 221 
an easy-to-use inhaler would enhance the likelihood that the medicine is inhaled correctly, which 222 
would increase its effectiveness, as measured and as perceived by patients. We suggest that further 223 
work in this field should be pursued for guiding drug developers to design better medicines. We also 224 
suggest that regulators, guideline writers, and payers should seek to understand the now well-225 
established concept of effectiveness and build it into their frameworks. 226 
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Traditional DBRCTs are deliberately designed to remove potential confounders such as 227 
device and patient preference, and thus are unlikely to allow modifiers of effectiveness to be 228 
expressed. Such trials rely on highly selected patient populations chosen for their compliance with 229 
treatment and study visits, who are typically socially stable, and have high adherence and near-230 
perfect inhaler technique; these patients are not representative of patients seen in everyday clinical 231 
practice. Trials such as the SLS show that patients in primary care, recruited with minimal exclusion 232 
criteria, can participate in a randomized controlled trial and yield data that complement the data 233 
obtained in traditional efficacy DBRCTs. 234 
Currently, we may be ignoring a crucial aspect of medicine assessment and, therefore, 235 
denying patients the opportunity for more effective therapies, while also discouraging effectiveness 236 
and patient-focused medicine development. 237 
 238 
Conclusions 239 
Evidence suggests that it is possible to design medicines to include a composite of features that can 240 
drive effectiveness. Improving a medicine’s effectiveness can provide a meaningful impact on 241 
patient outcomes, which can be demonstrated through appropriately designed pragmatic clinical 242 
trials. It is time to reconsider evidence hierarchies and bring more external validity to them. This is 243 
ultimately likely to benefit patients through encouraging patient-focused drug development, which 244 
includes consideration of the drivers of effectiveness and making more effective medicines available 245 
to patients. 246 
 247 
  248 
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